Pharma company recent update: Manas Jaiswal of manasjaiswal.com has a buy call Granules India Ltd. with an objective cost of Rs 106. The current market cost of Granules India Ltd. is Rs 98.45 Time period given by investigator is Intra Day when Granules India Ltd. cost can achieve the characterized target. Manas Jaiswal prescribed to keep a stop loss at Rs 94. Granules India Ltd. joined in 1991, is a midcap organization with a market top of Rs 2502.33 crore.
Granules India Ltd. – a pharma company key Products/Revenue Segments incorporate Pharmaceuticals which contributed Rs 1373.27 Crore to Sales Value (99.93 percent of Total Sales) and Scrap which contributed Rs.90 Crore to Sales Value (0.06 percent of Total Sales)for the year finishing 31-Mar-2017.
For the quarter finished 30-06-2018, the organization has detailed a Consolidated shares of Rs 453.24 Crore, down – 10.04 percent from last quarter Sales of Rs 503.82 Crore and up 19.67 percent from a year ago same quarter Sales of Rs 378.73 Crore Company has revealed net benefit after assessment of Rs 37.16 Crore in most recent quarter.
Granules India Ltd., consolidated in the year 1991, is a Mid Cap organization (having a market top of Rs 2536.64 Crore) working in Pharmaceuticals and social insurance area.
The pharma company best administration incorporates Dr.Krishna Murthy Ella, Dr.V V N K V Prasada Raju, Mr.A P Kurian, Mr.Arun Rao Akinepally, Mr.C Parthasarathy, Mr.Harsha Chigurupati, Mr.K B Sankar Rao, Mr.Krishna Prasad Chigurupati, Mr.L S Sarma, and Mrs. Uma Devi Chigurupati. The organization has Kumar and Giri as its audit of Rs as on 30-09-2018, the organization has a sum of 254,172,562 shares extraordinary, according to the report of Economic Times.
The post Manas Jaiswal Has Buy Call On Pharma Manufacturing Company Granules India Limited appeared first on OWLT Market.
from OWLT Market https://ift.tt/2yHVzSB
via IFTTThttps://ift.tt/2OlCCL9
No comments:
Post a Comment